Otilonium bromide exhibits novel antifungal activity against <i>Candida albicans</i> via regulating iron homeostasis.

ABSTRACT: Traditional antifungal drugs used against Candida albicans have several drawbacks, including the emergence of drug-resistant strains. In addition, developing novel antifungal agents requires long-term research and design. Drug repurposing, identifying and utilizing previously unknown functions of known drugs, such as antifungal activity, may be a quick method for mining efficient alternatives. Otilonium bromide (OB), an FDA-approved drug, is a quaternary ammonium compound used as a therapeutic drug for irritable bowel syndrome. We previously reported the inhibitory effect of OB against the spore germination of Cryptococcus neoformans. In this study, we found that the antifungal activity of OB against C. albicans was 2 μg/mL for both minimum inhibitory and fungicidal co

SUBMITTER: Hsu LH 

PROVIDER: S-EPMC12758266 | biostudies-literature | 2026 Dec

REPOSITORIES: biostudies-literature